[Federal Register Volume 88, Number 29 (Monday, February 13, 2023)]
[Notices]
[Pages 9279-9288]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-02930]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Establishment of the Coronavirus and Other Respiratory Viruses
Division
AGENCY: Centers for Disease Control and Prevention (CDC), the
Department of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: CDC has modified its structure. This notice announces the
establishment of the Coronavirus and other Respiratory Viruses Division
and other organizational components within the National Center for
Immunization and Respiratory Diseases (NCIRD), Deputy Director for
Infectious Diseases (DDID), CDC.
DATES: This reorganization was approved by the Secretary of HHS on
January 24, 2023, and became effective February 8, 2023.
SUPPLEMENTARY INFORMATION: Part C CDC of the Statement of Organization,
Functions, and Delegations of Authority of the Department of Health and
Human Services (45 FR 67772-76, dated October 14, 1980, and corrected
at 45 FR 69296, October 20, 1980, as amended most recently at 87 FR
51670-51675, dated August 23, 2022) is amended to reflect the
reorganization of NCIRD, DDID, CDC. Specifically, the changes are as
follows:
Under Part C, Section C-B, Organization and Functions, delete and/
or update functional statements for NCIRD in their entirety and replace
with the following:
NCIRD (CVG)
NCIRD prevents disease, disability, and death through immunization
and by control of respiratory and related diseases. In carrying out its
mission, NCIRD: (1) Provides leadership, expertise, and service in
laboratory and epidemiological sciences, and in immunization program
delivery; (2) conducts applied research on disease prevention and
control; (3) translates research findings into public health policies
and practices; (4) provides diagnostic and reference laboratory
services to relevant partners; (5) conducts surveillance and research
to determine disease distribution, determinants, and burden nationally
and internationally; (6) responds to disease outbreaks domestically and
abroad; (7) ensures that public health decisions are made objectively
and based upon the highest quality of scientific data; (8) provides
technical expertise, education, and training to domestic and
international partners; (9) provides leadership to internal and
external partners for establishing and maintaining immunization, and
other prevention and control programs; (10) develops, implements, and
evaluates domestic and international public health policies; (11)
communicates information to increase awareness, knowledge, and
understanding of public health issues domestically and internationally,
and to promote effective immunization programs; (12) aligns NCIRD's
focus with the overall strategic goals of CDC; (13) synchronizes all
aspects of CDC's pandemic preparedness and response from
[[Page 9280]]
strategy through implementation and evaluation; and (14) implements,
coordinates, and evaluates programs across NCIRD, DDID, and CDC to
optimize public health impact.
Office of the Director (OD) (CVG1)
(1) Provides leadership, expertise, and service in laboratory and
epidemiological sciences for respiratory and vaccine preventable
diseases and in immunization program delivery; (2) provides diagnostic
and reference laboratory services to relevant partnerships; (3) works
with DDID to ensure spending plans, budget planning, and budget
execution are in line with the overall infectious disease strategies
and priorities; (4) ensures that NCIRD's strategy is executed by the
divisions and aligned with overall CDC goals; (5) co-develops execution
strategies for NCIRD with the division directors; (6) provides program
and science quality oversight; (7) builds leadership at the division
and branch levels; (8) evaluates the strategies, focus, and
prioritization of the division research, program, and budget
activities; (9) identifies and coordinates synergies between NCIRD and
relevant partners; (10) ensures that policy development is consistent
and appropriate; (11) facilitates research and program activities by
providing leadership support; (12) proposes resource priorities
throughout the budget cycle; (13) ensures scientific quality, ethics,
and regulatory compliance; (14) fosters an integrated approach to
research, program, and policy activities; (15) liaises with HHS and
other domestic and international immunization and respiratory disease
partners as well as with NCIRD divisions; (16) coordinates center's
emergency response activities related to immunization issues and
complex acute respiratory infectious disease emergencies; (17) applies
communication science, media principles, and web design to support
NCIRD and CDC's efforts to reduce morbidity and mortality caused by
vaccine-preventable and respiratory diseases; ensuring that
communication distributed by the center is timely, accurate, clear and
relevant to intended audiences; (18) provides guidance for key
scientific and laboratory services in the functional areas of
extramural research (research and non-research), human studies
oversight and review, regulatory affairs; activities in the area of
space planning, advising, coordination and evaluation, safety
management and coordination, and shared services in controlled
correspondence, and programmatic services in the area of workforce and
career development; (19) provides and coordinates center-wide
administrative, management, and support services in the areas of fiscal
management, personnel, travel, procurement, facility management, and
other administrative services; and (20) manages the coordination of
workforce development and succession planning activities, and provides
human capital management, planning, and training consultation services.
Office of Informatics (CVG12)
(1) Manages all IT project costs, schedules, performances, and
risks; (2) provides expertise in leading application development
techniques in information science and technology to affect the best use
of resources; (3) performs technical evaluation and/or integrated
baseline reviews of all information systems' products and services
prior to procurement to ensure software purchases align with DDID
strategy; (4) provides access to quality data in support of
programmatic data analysis; (5) coordinates all enterprise-wide IT
security policies and procedures with the Office of the Chief
Information Officer and relevant enterprise governance bodies, such as
the IT and Data Governance; (6) ensures operations are in accordance
with CDC Capital Planning and Investment Control guidelines; (7)
ensures adherence to CDC enterprise architecture guidelines and
standards; (8) consults with users to determine IT needs and to develop
strategic and action plans; (9) participates in the evolution,
identification, development, or adoption of appropriate informatics
standards in conjunction with the DDID; and (10) provides leadership in
initiatives focused on data and IT modernization that aligns with CDC
agency goals for public health data modernization.
Office of Policy (CVG13)
(1) Serves as liaison with CDC/OD and other Centers, Institute,
Offices (CIO) policy offices, HHS and other government agencies, and
external partners on policy, program, legislative, and budgetary issues
related to NCIRD; (2) leads annual NCIRD budget formulation and
development of appropriations materials; (3) provides expertise and
guidance for strategic planning and performance measurement; (4)
oversees and coordinates NCIRD accountability activities, including
Government Accountability Office and Inspector General studies, audits
and reviews, as well as center responses to Freedom of Information Act
requests, and correspondence from partners, Congress, and the public;
(5) creates and provides briefing documents and materials for executive
leadership within NCIRD, DDID, and CDC on NCIRD's policy and
programmatic issues; (6) conducts legislative monitoring and analysis;
(7) provides NCIRD with leadership and advice in the management of
congressional and governmental relations; (8) works with NCIRD
divisions to coordinate policy requests across the center; (9) manages
cross-cutting policy issues within NCIRD and, as appropriate, with
other CIO and OD offices within CDC; and (10) collaborates across NCIRD
and CDC to build and maintain partnerships that support NCIRD's
domestic and global goals and initiatives, including promoting
vaccination across the lifespan; prevention, detection and control of
respiratory diseases; and preparedness for pandemics and other
respiratory disease outbreaks.
Office of Health Communications Science (CVG15)
(1) Supports NCIRD's mission through the planning, development,
implementation, and evaluation of science-based health communication
activities and programs; (2) applies communication science, media
principles, and web design to support NCIRD and CDC's efforts to reduce
morbidity and mortality caused by vaccine-preventable and respiratory
diseases; (3) conducts projects that translate scientific and medical
information into messages for a variety of audiences using an array of
media/formats; (4) improves understanding of vaccine benefits and risks
among partners, healthcare providers and public audiences; (5) improves
understanding among specialized audiences such as policy-makers and
public health officials nationally and internally of NCIRD's work; (6)
supports public health partners via technical assistance and other
methods; (7) demonstrates best practices in writing using plain
language and health literacy principles, creating culturally
appropriate materials; (8) coordinates CDC's pandemic influenza
communication preparedness activities; (9) leads the development and
implementation and evaluation of major cross cutting communication
campaigns for vaccines preventable diseases; and (10) conducts
behavioral and communication research to ensure that messages and
strategies are clear, relevant, and potentially impactful to intended
audiences.
[[Page 9281]]
Office of Management & Operations (CVG16)
(1) Plans, coordinates, directs and provides advice and guidance on
management and administrative operations of NCIRD in the areas of
fiscal management, personnel, human capital, workforce training and
development, travel, records management, facility management, and other
administrative related services; (2) prepares and distributes annual
budget plans and provides overall direction for planning and management
oversight of allocated resources; (3) provides guidance on NCIRD
requirements related to intramural and extramural activities,
purchases, and agreements; (4) reviews the effectiveness and efficiency
of the operation and administration of all NCIRD programs; (5) develops
and implements administrative policies and procedures; (6) prepares
special reports and studies in the administrative management areas; and
(7) coordinates workforce development and succession planning
activities for and with the center, providing human capital management,
planning, and training consultation services to manage evolving
workforce needs and skillset requirements.
Office of Science (CVG17)
(1) Links strategies and priorities of the primarily programmatic-
focused NCIRD divisions with those of primarily disease-based
divisions; (2) facilitates development and ongoing implementation of
integrated infectious respiratory disease (including influenza)
surveillance, research and prevention, and control activities across
the divisions, both domestically and globally, including supporting
implementation of NCIRD's respiratory diseases strategic prevention
priorities; (3) meets with other CDC CIOs working in the area of
respiratory diseases; (4) coordinates and facilitates NCIRD's overall
respiratory and vaccine preventable disease scientific/research agenda;
(5) assumes responsibility for the protection of human research
subjects, scientific review, clearance of manuscripts and other written
materials; (6) provides planning and coordination of overall
surveillance strategies, preparedness, response, and prevention
effectiveness related to a center-wide public health scientific agenda
and quantifies how programs and activities promote cost-effective and
high impact prevention strategies with respect to immunization and
other vaccine-preventable disease programs; (7) provides leadership
(agency and center-wide) for vaccine-preventable and respiratory
disease surveillance to include guidance and coordination of NCIRD
surveillance activities and systems, leadership on issues related to
internal and external integration of CDC surveillance activities, and
alignment with enterprise-wide data and IT governance and modernization
strategy; (8) coordinates, facilitates, and integrates domestic and
international respiratory and vaccine-preventable disease surveillance
activities through existing methods while developing new approaches,
tools, and analyses for these activities; (9) fosters a
multidisciplinary approach to epidemiology, statistics, informatics,
laboratory methods, and evaluation; (10) provides leadership,
expertise, and service in laboratory science; (11) represents NCIRD's
interests in cross-cutting laboratory services in DDID which include,
but are not limited to, laboratory information systems, quality
management systems, and bioinformatics; (12) ensures a safe working
environment in NCIRD laboratories; (13) collaborates effectively with
other centers and offices in carrying out its functions; (14) manages
CDC's intellectual property (e.g., patents, trademarks, copyrights) and
promotes the transfer of new technology from CDC research to the
private sector to facilitate and enhance the development of diagnostic
products, vaccines, and products to improve occupational safety; (15)
provides oversight, guidance and coordination relating to the
application of social and behavioral sciences to support impactful
research and programs to achieve healthy behavior change; (16)
coordinates and tracks health equity science and program activities
within NCIRD and with partners; and (17) supports research,
surveillance, education, training, and program development to achieve
healthy equity and reduce health disparities.
Office of Global Health, Preparedness, and Response (CVG18)
(1) Advises NCIRD and CDC leadership on global health and pandemic
preparedness related to current and known threats such as coronavirus
disease 2019 (COVID-19) and influenza, and to emerging pandemic
threats; (2) provides strategic leadership for CDC in the areas of
pandemic preparedness and response and global health related to
respiratory and vaccine preventable diseases including establishing
NCIRD priorities, promoting science, policies, and new programs; (3)
coordinates NCIRD efforts related to funding and budgets for global
health security and pandemic preparedness and response; (4) supports
NCIRD's work across CDC and the federal government on global health
security, respiratory diseases, and pandemic preparedness and response;
and (5) coordinates across NCIRD, CDC, and with partners to plan for
and exercise responses to pandemic and other threats.
Immunization Services Division (ISD) (CVGB)
ISD protects individuals and communities from vaccine-preventable
diseases across the lifespan through: provision of federal funds and
contracts to purchase and distribute vaccines; provision of technical
and financial support for immunization programs, partners, and for
efforts to increase equity in immunization; provision of provider,
patient, and public immunization education and communication;
surveillance of vaccination coverage and vaccine attitudes; and
evaluation and research to identify root causes of under vaccination
and vaccine inequity.
ISD Office of the Director (CVGB1)
(1) Supports ISD's mission through leadership across the branches
related to domestic vaccination efforts and vaccine-preventable disease
preparedness and response elements and links strategies and priorities
with other NCIRD divisions; (2) facilitates development and ongoing
implementation of vaccination coverage surveillance, health services
and economic research, and program evaluation across ISD branches; (3)
provides direct management, oversight, and execution of national
vaccine supply contracts; (4) provides direct management and execution
of procurement requisitions, contracts, and cooperative agreements, and
performs administrative tasks related to initiating, processing, and
maintaining interagency agreements; (5) provides direct management and
execution of human resources, administrative functions, and workplace
climate and facility management across ISD; (6) provides guidance
related to and protection of human research subjects, Office of
Management and Budget and Paperwork Reduction Act compliance, and
scientific initiatives across ISD branches; (7) furthers data strategy,
IT governance, and data-related policy across the division, through
coordinated work across ISD; (8) provides leadership for activities in
ISD related to health equity, including improving equity in access to
vaccination opportunities and vaccination coverage rates across
different populations; (9) coordinates programs and activities to help
achieve
[[Page 9282]]
and sustain increased vaccination coverage among uninsured and
underinsured adults; (10) coordinates and supports activities across
the division related to cross-cutting topics, such as emergency
preparedness, clinical expertise, jurisdictional coordination, and
vaccine confidence and demand; (11) provides direct management and
oversight for division-wide communications and policy, including
liaisons to the branches; (12) serves as liaison to other policy
offices, other government agencies, and external partners on policy,
program, legislative, and budgetary issues related to ISD; (13) manages
and executes cross-cutting communications to support ISD's mission to
protect individuals and communities from vaccine-preventable diseases;
(14) promotes internal awareness of division initiatives and guidance
through timely, accurate, clear, and relevant communications; (15)
provides technical assistance to ISD branches in the development and
revision of operational manuals, job aids, and web pages; (16) manages
the all-jurisdiction email account by maintaining distribution lists
(in collaboration with ISD branches) and disseminating messaging to
jurisdictions and partners on behalf of ISD and its branches and
programs.
Immunization Operations and Services Branch (CVGBB)
(1) Serves as CDC's primary interface with the state, local, and
territorial health department immunization programs funded by
cooperative agreements related to Vaccines for Children (VFC), Section
317, and other programs that support immunization across the lifespan,
supporting them with development, implementation, assessment, and
promotion of vaccination-related activities with the goal of achieving
and sustaining high and equitable vaccination coverage levels across
the lifespan; (2) serves as ISD's lead in the management, processing,
and monitoring of the funding provided through the cooperative
agreements related to VFC, Section 317, and other programs supporting
immunization across the lifespan; (3) administers the operations of the
VFC, Section 317, and other appropriate programs for eligible
jurisdictions; (4) provides technical assistance to jurisdictions on
program implementation for child, adolescent, and adult activities,
including implementation of all components of the cooperative
agreements; (5) provides subject-matter expertise on adult immunization
program implementation and guidance; (6) monitors performance of
recipients of the cooperative agreements related to VFC, Section 317,
and other programs supporting immunization across the lifespan; (7)
oversees management and operations of jurisdiction-vaccination provider
engagement programs and efforts (i.e., VFC and Section 317 quality
assurance, quality improvement [in cooperation with the Applied
Research, Implementation Science, and Evaluation Branch] perinatal
hepatitis B prevention, and vaccine accountability [in cooperation with
the Vaccine Supply and Assurance Branch]).
Vaccine Supply and Assurance Branch (CVGBC)
(1) Manages logistics for the public sector vaccine supply chain;
(2) supports supply chain immunization activities carried out by state,
local, and territorial health department immunization programs and
their enrolled providers, funded by cooperative agreements related to
VFC, Section 317, or other programs that support immunization across
the lifespan; (3) provides planning, purchasing, ordering,
distribution, and management of vaccine supply shortages and
constraints; (4) establishes and manages contracts for the purchase of
vaccines across the lifespan; (5) creates and maintains pediatric
vaccine stockpiles for the VFC program; (6) tracks and monitors
seasonal influenza vaccine distribution; (7) maintains subject matter
expertise and provides technical assistance related to jurisdiction
vaccine planning activities and vaccine storage and handling; (8)
serves as the business owner for CDC's vaccine order management system
(VTrckS); engage in strategic planning for the modernization and
defect/enhancement testing for VTrckS [in collaboration with the
Informatics and Data Analytics Branch]; provides support and training
for jurisdiction users of VTrckS; (9) manages contracts that provide
technical, operational, and user support for VTrckS; (10) uses vaccine
purchase and order data to support activities within the branch,
respond to internal and external data calls, provide jurisdiction
feedback, and collaborate on CDC-sponsored evaluation activities.
Informatics and Data Analytics Branch (CVGBE)
(1) Provides leadership, technical assistance, technology tools,
data quality assurance, and resource support to develop capacity for a
nationwide network of fully operational and integrated immunization
information systems (IISs); (2) increases the quality of IIS data
across the lifespan and system functionality and security by
identifying, developing, implementing, promoting, and evaluating
standards and best practices in collaboration with other federal
agencies and partners; (3) supports exchange of high-quality IIS data
between jurisdictions' clinical, administrative, public health
immunization stakeholders, and federal partners; (4) promotes the
effective use of IIS data and systems to support vaccination providers,
public health programs, and other immunization stakeholders; (5)
monitors, evaluates, and reports on IIS data to improve operations and
immunization program outcomes; (6) maintains informatics capability and
information technology tools to support immunization programs at the
provider, jurisdiction, and federal level; and (7) influences health
information technology policies and standards to improve the quality of
immunization data submitted by healthcare systems.
Surveillance and Epidemiology Branch (CVGBG)
(1) Leads domestic vaccination coverage and vaccine confidence and
demand assessment across the lifespan; (2) collects, analyzes, and
disseminates accurate and timely data for action--including data
related to vaccination coverage, utilization data, and related
information from available data sources (including but not limited to
data from national surveys, health systems, and medical claims) in
conjunction with subject matter experts in other ISD branches as
appropriate; (3) assesses equity in vaccination coverage and vaccine
confidence and demand among racial/ethnic minorities and other
populations disproportionately affected by health inequities; (4) in
conjunction with other ISD branches, assists national, state, and local
immunization programs in collection, analysis, interpretation, and use
of vaccination coverage and vaccine confidence and demand assessment to
guide policy and program activities; (5) conduct and manage the family
of surveys under the National Immunization Survey contract to assess
vaccination coverage and behavioral and social drivers of vaccination;
and (6) evaluate and find methods to improve the usefulness of existing
and potential new data sources for assessment of vaccination coverage
and behavioral and social drivers of vaccination.
Health Education and Communication Branch (CVGBH)
(1) Provides education and communication materials and resources
[[Page 9283]]
to improve knowledge and acceptance of vaccines among healthcare
providers and the public to increase vaccine uptake across the
lifespan, thus reducing vaccine-preventable diseases; (2) provides
education and communication materials and resources to improve clinical
knowledge among healthcare providers and other healthcare personnel
about the proper storage, handling, preparation, and administration of
vaccines to help ensure vaccine safety; (3) collaborates across NCIRD
to develop communication strategies to increase vaccinations across the
lifespan; (4) develops and disseminates, by a variety of mechanisms,
domestic immunization messages, materials, educational resources, and
training for healthcare providers and patients related to ISD's
scientific, clinical, and programmatic work; (5) provides technical
assistance for healthcare providers, state and local health
departments, and other groups on communication science and
implementation, scalable programmatic action, and evaluation of
education and communication strategies to improve vaccine confidence
and vaccination coverage rates; (6) provides continuing education
credits for immunization-related education and training products; (7)
leads the Advisory Committee on Immunization Practices (ACIP) Child and
Adolescent and Adult Immunization Schedules Work Group and General Best
Practices Work Group, participates in other ACIP work groups, and
develops and promotes resources related to ACIP schedules and
recommendations; (8) develops and promotes social media and other
initiatives to combat immunization misinformation and/or disinformation
and promote vaccine confidence and equity; (9) collaborates with ISD
policy, communication, and implementation science functions to address
communication science needs; (10) responds to clinically or
programmatically relevant immunization inquiries via NIP-INFO, an email
inquiry service for health departments and healthcare providers; and
(11) develops vaccine information statements as required by law.
Applied Research, Implementation Science, and Evaluation Branch (CVGBJ)
(1) Synthesizes literature/data and conducts health services and
economic research to understand reasons for under-vaccination and
vaccine inequities across the lifespan; (2) designs strategies to
increase vaccination coverage, equity, and confidence, and assess
strategy effectiveness; (3) translates and adapts evidence-based
strategies for scalable programmatic action; (4) designs ISD's quality
improvement activities; define their standards and requirements for
implementation and for data collection, reporting, and sharing; (5)
provides technical assistance and facilitate research and evaluation
capacity building among CDC-funded immunization programs; (6) supports
program effectiveness activities conducted by CDC-funded immunization
programs; (7) monitors trends in access to vaccines, vaccine knowledge,
attitudes, and perceptions, including vaccine confidence; (8) provides
division-wide subject matter expertise on evaluation; and (9) conducts
over-arching evaluation of the national immunization program to inform
program improvement.
Field Services Branch (CVGBK)
(1) Provides support to the state, local, and territorial health
department immunization programs funded by cooperative agreements
related to VFC, Section 317, and other programs supporting immunization
across the lifespan for immunization program implementation through the
assignment of CDC staff as requested by jurisdictions to address gaps
in capacity; (2) based on the agreements with each jurisdiction,
provides official supervision and high-level training of staff assigned
to health departments to assist with jurisdiction immunization program
operations; and (3) supports the needs and provides tools for staff
embedded in jurisdictions and local health departments.
Partnership and Health Equity Branch (CVGBL)
(1) Collaborates with public health partner groups to achieve
national immunization program goals and scalable programmatic action;
(2) partners with national, state, local, and community-based
organizations to achieve greater equity in access to and demand for
administration of vaccines across the lifespan; (3) partners with non-
governmental professional organizations to support immunization
recommendations, and education, communication, training, and quality
improvement strategies; (4) partners with other federal agencies to
ensure coordination of efforts related to equity and vaccination; (5)
provides technical assistance and capacity-building support to funded
and unfunded partners to achieve immunization and equity goals; (6)
facilitates a shared learning forum and learning opportunities for
partners to provide strategies and resources on promoting vaccine
equity; (7) monitors opportunities for future partnerships, especially
those that serve adult, underrepresented, and disproportionately
affected populations; (8) evaluates funded partnerships to ensure that
projects are meeting workplan objectives and other requirements; and
(9) monitors and supports needs of immunization partners external to
ISD.
Influenza Division (ID) (CVGD)
ID improves global control and prevention of seasonal and novel
influenza and improves influenza pandemic preparedness and response. In
collaboration with domestic and global partners, ID: (1) Builds
surveillance and response capacity; (2) monitors and assesses influenza
viruses and illness; (3) improves vaccines and other interventions; and
(4) applies research to provide science-based enhancement of prevention
and control policies and programs.
ID Office of the Director (CVGD1)
(1) Provides vision, leadership, and direction for the division;
(2) fosters external partnerships and cross-cutting activities that
support quality science and strong global partnerships; (3) provides
leadership and guidance in policy formulation; (4) provides technical
expertise and leadership for national and international pandemic
preparedness activities; and (5) provides technical expertise for
communications, public health guidance, informatics, epidemiologic, and
laboratory science, and reagent resources.
Virology, Surveillance, and Diagnosis Branch (CVGDB)
(1) Conducts comprehensive antigenic, phenotypic, genotypic,
structural, and evolutionary characterization of human and animal
influenza viruses; (2) performs genetic and antigenic pandemic risk
assessment of novel influenza viruses; (3) develops and evaluates novel
and seasonal candidate vaccine viruses; (4) provides expert guidance on
influenza vaccine virus selection; (5) develops methods to detect and
characterize influenza viruses; and (6) trains and supports
laboratories that perform influenza testing.
Epidemiology and Prevention Branch (CVGDC)
(1) Conducts surveillance, research, modeling, and forecasting
activities to better understand and monitor the epidemiology of
influenza viruses and disease; (2) improves understanding of
[[Page 9284]]
the effectiveness of influenza antiviral drugs, vaccines, and non-
pharmaceutical interventions; (3) assists state and local health
departments to conduct surveillance and optimize activities related to
the detection and response to emerging and novel influenza viruses; (4)
supports influenza vaccine policy; and (5) supports influenza pandemic
preparedness activities.
Immunology and Pathogenesis Branch (CVGDE)
(1) Increases knowledge and improves understanding of immunity and
immune correlates of protection; (2) develops and improves vaccines;
(3) determines virus and host factors that impact virulence and
transmission of influenza viruses; (4) conducts immunologic and
virologic pandemic risk assessment of novel influenza viruses; and (5)
trains and supports laboratories that perform immunologic testing.
Global Influenza Branch (CVGDG)
(1) Supports capacity building to improve global surveillance for
influenza viruses and disease; (2) conducts surveillance, program
evaluations, research, and modeling activities to improve our
understanding of global influenza; (3) assists with detection and
response to emerging and novel influenza viruses outside the United
States; (4) promotes prevention and control activities including the
expanded use of influenza vaccines globally; and (5) supports global
pandemic preparedness activities.
Division of Viral Diseases (DVD)(CVGE)
DVD prevents disease, disability, and death through immunization
and control of enteric, and related viral diseases. In carrying out
this mission, DVD: (1) Conducts surveillance and related activities to
determine patterns of infection and disease and impact of prevention
programs; supports and provides technical assistance to state and local
health departments to conduct surveillance and related activities; (2)
conducts epidemiologic and laboratory studies to define patterns of,
and risk factors for, infection, disease, and disease burden; estimates
vaccine effectiveness, determines cost effectiveness of vaccines, and
evaluates other aspects of immunization programs; identifies and
evaluates non-vaccine prevention strategies; and provides epidemiologic
and laboratory expertise to other Nation Centers (NCs), collaborators,
and partners on vaccination and other prevention strategies; (3)
provides consultation on viral vaccine preventable, and enteric
diseases, and the use of vaccines and other measures to prevent
infections; (4) provides consultation and support and/or participates
in investigations of viral vaccine preventable and enteric viral
diseases domestically and internationally, and recommends appropriate
control measures; (5) provides scientific leadership and advice,
analyzes and synthesizes available data, and develops science-based
statements for use of viral vaccines to ACIP and other groups to
support the development and evaluation of immunization practices and
policies domestically and internationally; (6) provides laboratory
support for surveillance and epidemiologic studies and maintains
reference/diagnostic services and expertise; (7) conducts studies of
immunology and pathogenesis of disease and the biologic, biochemical,
genetic and antigenic characteristics of the agents; (8) develops,
evaluates, and improves diagnostic methods and reagents, and transfers
assays and techniques to other public health laboratories; (9)
facilitates and participates in the development and evaluation of
antiviral compounds, vaccines, and vaccination programs; (10) provides
and supports public health training; (11) responds to and assists
internal and external partners on other public health problems of
national and international significance, as needed; (12) provides
technical support to state immunization programs for all aspects of
vaccine-preventable diseases and their vaccines; (13) provides
leadership in vaccine science; and (14) supports CDC's Immunization
Safety Office (ISO) in vaccine safety risk assessment and leadership in
vaccine safety risk management.
DVD Office of the Director (CVGE1)
(1) Manages, directs, coordinates and monitors the activities of
the division; (2) provides overall guidance and direction for the
division's epidemiologic, surveillance, research, laboratory, outbreak
response, and other scientific and immunization-related activities; (3)
sets short- and long-term programmatic goals and outlines strategic
achievements in alignment with NCIRD priorities; (4) monitors and
evaluates progress of division- and branch-led programs, promotes
program improvements, and facilitates strategic decision-making; (5)
provides analysis and facilitates strategic use of public health
policies and operational procedures for continuous risk management and
operational efficiencies; (6) identifies needs and allocates resources
for ongoing and new initiatives and assigns responsibilities for their
development; (7) communicates division public health messages to
internal and external audiences via conventional media, web, social
media, professional organizations, and other venues, to maximize impact
of division programs; (8) provides leadership and guidance in policy
formulation, partnerships, program planning and development, program
management, and operations of the division; (9) provides division
leadership, expertise, and technical collaboration for the application
of statistics, economics, operations research, geospatial analysis,
other quantitative sciences, informatics, and data management to
prevent disease, disability and death through immunization and control
of enteric, and other viral diseases; (10) provides next-generation
sequencing laboratory support for method development and bioinformatics
infrastructure across division and with external partners; (11)
provides leadership for division informatics, data, and surveillance
modernization initiatives; (12) prepares, reviews, and coordinates
informational, scientific, and programmatic documents; (13) assures the
overall quality of the science conducted by the division and provides
guidance and new initiatives to support the enhancement of laboratory
quality and bio-safety; (14) oversees and facilitates the division's
scientific support to other groups within CDC and national and
international public health and healthcare partners; (15) guides and
facilitates efficient coordination and cooperation for administrative,
programmatic, and scientific activities within the division and with
other groups inside and outside of CDC; and (16) supports the division
related to Management & Operations functions such as budget, program
resource management, extramural administration, and human resource
management.
Polio and Picornavirus Branch (CVGEC)
(1) Provides laboratory assistance, technical expertise and support
for surveillance and related activities to monitor impact of
vaccination and other prevention programs, and determine patterns of
infection and disease due to poliovirus and other human picornaviruses;
(2) provides laboratory support and technical expertise for
epidemiologic and laboratory studies to define patterns and risk
factors for infection, disease, and disease burden; (3) studies
vaccine-related issues; (4) identifies and evaluates non-vaccine
[[Page 9285]]
prevention strategies; (5) provides laboratory consultation and
technical expertise regarding use of vaccines and other measures to
prevent infections to other NCs, collaborators, and partners; (6)
provides laboratory and epidemiologic consultation and support and/or
participates in investigations of national and international outbreaks
of viral vaccine-preventable and enteric viral diseases; (7) provides
laboratory leadership and technical expertise to develop science-based
statements to Global Polio Eradication Initiative, ACIP, and other
groups to support the development and evaluation of immunization
practices and policies in the United States and internationally; (8)
provides epidemiology and laboratory consultation and support and/or
participates in investigations of national and international outbreaks
of viral diseases, and recommends appropriate control measures; (9)
provides scientific leadership and advice, in both epidemiologic and
laboratory areas; (10) provides support for surveillance and
epidemiologic studies and maintains reference/diagnostic services and
expertise; (11) conducts studies of immunology and pathogenesis of
disease and the biology, biochemical, genetic, and antigenic
characteristics of the agents; (12) develops, evaluates, and improves
diagnostic methods and reagents, transfers assays and techniques to
national and international public health laboratories, and provides and
supports training for laboratorians; (13) facilitates and participates
in the development and evaluation of antiviral compounds, vaccines, and
vaccination programs; (14) responds to and assists internal and
external partners on other public health problems of national and
international significance as needed; and (15) serves as the National
Reference Laboratory (poliovirus and enteroviruses) and World Health
Organization (WHO) Global Polio Specialized Reference Laboratory.
Viral Vaccine-Preventable Diseases Branch (CVGED)
(1) Conducts surveillance to determine patterns of infection and
disease, provides laboratory assistance, technical expertise, and
support for surveillance and related activities to monitor the impact
of vaccination on the prevention of viral disease; (2) conducts
epidemiologic and laboratory studies to define patterns of and risk
factors for infection, disease, and disease burden; (3) estimates
vaccine effectiveness, evaluates other aspects of immunization
practices; (4) identifies and evaluates non-vaccine prevention
strategies; (5) provides epidemiological and laboratory expertise and
technical support to other NCs, collaborators, and partners across
center working groups on vaccines and other prevention strategies; (6)
supports the development of vaccine practices and policies by providing
consultation and epidemiologic and laboratory expertise to other
federal agencies, state health departments, ministries of health, WHO,
Pan American Health Organization (PAHO), private industry, academia,
and other governmental organizations on viral vaccine-preventable
diseases, and on the use of vaccines and other measures to prevent
infections; (7) provides epidemiologic and laboratory consultation and
support and/or participates in investigations of national and
international outbreaks of viral vaccine-preventable diseases and
recommends appropriate control measures; (8) assists internal and
external partners on other public health problems of national and
international significance; (9) provides scientific leadership and
advice, analyzes available data, and develops science-based statements
for viral vaccines to the ACIP and other groups to support the
development and evaluation of immunization practices and policies in
the United States and internationally; (10) responsible for human
papilloma virus (HPV), measles, mumps, rubella (MMR), zoster, and
varicella vaccine policy in the United States by working with ACIP;
(11) provides and supports public health training; (12) responds to
public inquires and prepares communication materials; (13) works with
health economists to determine cost effectiveness of vaccination
strategies; (14) provides laboratory support for surveillance and
epidemiologic studies and maintains reference and diagnostic services
and expertise; (15) assists in investigation of adverse events
following vaccination; (16) conducts studies of immunology and
pathogenesis of disease and the biological, biochemical, genetic, and
antigenic characteristics of viral agents; (17) develops, evaluates,
and improves diagnostic methods and reagents; (18) transfers assays and
techniques to other public health laboratories; (19) provides and
supports laboratory training; (20) serves as the National Reference
Laboratory for MMR, and varicella zoster virus and the PAHO Regional
and WHO Global Specialized Laboratory for measles and rubella; (21)
collaborates with CDC's HPV laboratory in conducting epidemiologic
investigations; (22) facilitates and participates in the development
and evaluation of vaccines, and vaccination programs; and (23) conducts
studies to measure the immune response to viral vaccines and population
immunity.
Viral Gastroenteritis Branch (CVGEE)
(1) Provides epidemiologic and laboratory assistance to studies and
related activities to better understand the evolution, (molecular)
epidemiology and immunity of rotavirus, norovirus, and other
gastroenteritis viruses; (2) provides consultation on the safety and
impact of rotavirus vaccination and other prevention programs
(rotavirus, norovirus); (3) provides consultation and technical
assistance to state and local health departments to monitor the burden
of disease and epidemiology of gastroenteritis virus infections; (4)
provides consultation and support on the research and development of
new rotavirus vaccines and other prevention technologies; (5) provides
consultation, support and/or participates in investigations of national
and international outbreaks of viral vaccine-preventable and other
enteric viral diseases, and recommends appropriate control measures;
(6) provides scientific leadership and advice, analyzes available data,
and develops science-based statements for rotavirus vaccines to ACIP
and other groups to support the development and evaluation of
immunization practices and policies in the United States and
internationally; (7) provides and supports public health training; (8)
responds to and assists internal and external partners on other public
health problems of national and international significance, as needed;
(9) serves as the National Reference Laboratory for rotavirus,
norovirus and other agents of viral gastroenteritis; and (10) serves as
the WHO Global Reference Center for Rotavirus and other agents of viral
gastroenteritis.
Division of Bacterial Diseases (DBD) (CVGG)
DBD prevents and controls illness and death from vaccine-
preventable and other respiratory bacterial diseases, in the United
States and worldwide, through leadership in epidemiologic and
laboratory science and vaccine policy. DBD plays a critical role in
outbreak response, surveillance and epidemiologic research, laboratory
diagnosis and pathogen characterization, and vaccine development, and
provides scientific support for development of vaccine policy and
public health guidance to control vaccine-preventable and other
respiratory bacterial diseases. In carrying out its mission, DBD: (1)
Conducts and assists state and local
[[Page 9286]]
health departments to conduct surveillance, including surveillance for
antimicrobial resistance in the bacteria under the division's purview,
and prepares and distributes surveillance information; (2) conducts
epidemiologic and laboratory studies to define etiology, patterns of
disease, disease burden, and risk factors; determines safety,
effectiveness, and cost effectiveness of vaccines, updates immunization
policy, and evaluates other aspects of immunization practices; and
identifies and evaluates other (non-vaccine) prevention strategies; (3)
provides consultation on the use of bacterial vaccines and other
measures to prevent infections; (4) participates, provides
consultation, and supports investigations of outbreaks, epidemics, and
other public health problems in the United States and internationally,
and recommends and evaluates appropriate control measures; (5) provides
scientific leadership for development and evaluation of immunization
policy related to vaccines in the United States by compiling and
analyzing information on vaccine-preventable diseases and helping
prepare statements on bacterial vaccines for the ACIP and other groups
to support the development and evaluation of immunization policy; in
international settings, provides guidance and technical expertise on
vaccine-preventable disease policy development; (6) provides laboratory
support for surveillance and epidemiologic studies and reference
diagnostic services, to state and local health departments, other
federal agencies, and national and international health organizations;
(7) conducts studies of the biology, biochemical, genetic, and
antigenic characteristics, immunology, and pathogenesis of disease; (8)
develops, analyzes, and improves diagnostic methods and reagents; (9)
facilitates development and evaluation of immunologic compounds,
vaccines, and vaccination programs; (10) provides intramural and
extramural assistance with professional training; (11) assists internal
and external partners with other public health problems of national and
international significance when needed; (12) provides technical support
to state immunization programs for all aspects of vaccine-preventable
diseases and their vaccines; (13) provides leadership in vaccine
science; and (14) supports CDC's ISO in vaccine safety risk assessment
and leadership in vaccine safety risk management.
DBD Office of the Director (CVGG1)
(1) Directs, coordinates, and manages the programs and activities
of the division; (2) provides leadership and guidance on policy,
program planning and development, program management, and operations;
(3) coordinates or assures coordination with the appropriate CDC, DDID,
and NCIRD offices on administrative and program matters; (4) reviews,
prepares, and coordinates congressional testimony and briefing
documents related to bacterial respiratory and vaccine-preventable
diseases, and analyzes programmatic and policy implications of
legislative proposals; (5) serves as CDC, DDID, and NCIRD's primary
internal and external communications contact regarding bacterial
respiratory and vaccine-preventable disease issues; (6) advises CDC,
DDID, and NCIRD on policy and communications matters concerning the
division's programs and activities; (7) assures the overall quality of
the science conducted by the division; (8) coordinates division
activities on cross-cutting agency initiatives; (9) guides and
coordinates division laboratories to implement quality management
systems and maintain safety; (10) guides and facilitates efficient
coordination and cooperation for administrative, programmatic, and
scientific activities within the division, and with other groups in and
outside of CDC; (11) provides statistical consultation for
epidemiologic and laboratory research studies conducted by the
division, including developing new methods for statistical
applications; and (12) provides a center of excellence for the study of
immunologic response to infection, vaccination, and therapeutic
interventions against bacterial diseases.
Respiratory Diseases Branch (CVGGB)
(1) Provides assistance in control of epidemics and works to
improve control and prevention of respiratory and other syndromes
caused by Streptococcus pneumoniae, group A and group B streptococci,
and atypical respiratory bacteria (Legionella, Mycoplasma, and
Chlamydia species), as well as community-acquired drug resistant
bacterial infections, community-acquired pneumonia, otitis media, and
neonatal sepsis; (2) develops, implements, and evaluates prevention
methods for these diseases, including vaccines and non-vaccine
strategies; (3) provides consultation and support to domestic and
international partners on use of vaccines and other prevention measures
to reduce bacterial respiratory diseases; (4) coordinates activities
within and outside the division related to Active Bacterial Core
surveillance with the Emerging Infections Program states, and assists
with coordination of other surveillance platforms that include
bacterial respiratory diseases; (5) provides reference and diagnostic
activities for respiratory bacterial diseases and for the
identification of unknown gram positive cocci; (6) develops and
evaluates new diagnostic methods for bacterial respiratory pathogens;
(7) develops, maintains, and implements genetic analyses of bacteria to
enhance surveillance programs, outbreak investigations, and public
health research; and (8) collaborates with other CDC groups, state and
federal agencies, ministries of health, WHO, PAHO, private industry,
academia, and other governmental organizations involved in public
health.
Meningitis and Vaccine Preventable Diseases Branch (CVGGC)
(1) Provides assistance in control of endemic and epidemic disease
and exploits opportunities to improve control and prevention of
bacterial illness including: meningococcal disease, Haemophilus
influenzae infections, diphtheria, pertussis, tetanus, and bacterial
meningitis syndrome; (2) provides reference and diagnostic activities
for agents causing these diseases; (3) provides cross-cutting vaccine
responsibilities for DBD and develops, implements, and evaluates
prevention strategies for these bacterial diseases; (4) develops,
implements, and evaluates vaccines and vaccine candidates for these
bacterial diseases; (5) conducts surveillance and epidemiological
research for meningococcal disease, H. influenzae infections,
diphtheria, pertussis, tetanus, and bacterial meningitis syndrome; (6)
maintains WHO Collaborating Center for Control and Prevention of
Epidemic Meningitis; and (7) collaborates with other CDC groups, state
and federal agencies, ministries of health, WHO, PAHO, private
industry, and other governmental organizations involved in public
health.
Coronavirus and Other Respiratory Viruses Division (CRVD) (CVGH)
CRVD prevents disease, disability, and death through immunization
and control of coronaviruses, respiratory, and other related viral
diseases. In carrying out this mission, CRVD: (1) Conducts surveillance
and related activities to determine patterns of infection and disease
and impact of prevention programs; (2) supports and provides technical
assistance to state and local health departments to conduct
surveillance and related activities; (3) conducts epidemiologic and
laboratory studies to define patterns of, and risk factors for,
infection, disease, and
[[Page 9287]]
disease burden; (4) estimates vaccine effectiveness, determines cost
effectiveness of vaccines, and evaluates other aspects of immunization
programs; (5) identifies and evaluates non-vaccine prevention
strategies and provides epidemiologic and laboratory expertise to other
NCs, collaborators, and partners on vaccination and other prevention
strategies; (6) provides consultation on viral vaccine preventable, and
enteric diseases, and the use of vaccines and other measures to prevent
infections; (7) provides consultation and support and/or participates
in investigations of respiratory viral diseases domestically and
internationally, and recommends appropriate control measures; (8)
analyzes and synthesizes available data to support the development and
evaluation of immunization practices and policies domestically and
internationally; (9) provides laboratory support for surveillance and
epidemiologic studies and maintains reference/diagnostic services and
expertise; (10) conducts studies of immunology and pathogenesis of
disease and the biologic, biochemical, genetic and antigenic
characteristics of the agents; (11) develops, evaluates, and improves
diagnostic methods and reagents; (12) transfers assays and techniques
to other public health laboratories; (13) facilitates and participates
in the development and evaluation of antiviral compounds, vaccines, and
vaccination programs; (14) provides and supports public health
training; (15) responds to and assists internal and external partners
on other public health problems of national and international
significance, as needed; (16) provides technical support to state
immunization programs for all aspects of vaccine-preventable diseases
and their vaccines; (17) provides leadership in vaccine science; and
(18) supports CDC's ISO in vaccine safety risk assessment and
leadership in vaccine safety risk management.
CRVD Office of the Director (CVGH1)
(1) Manages, directs, coordinates and monitors the activities of
the division; (2) provides overall guidance and direction for the
division's epidemiologic, surveillance, research, laboratory, outbreak
response, and other scientific and immunization-related activities; (3)
sets short- and long-term programmatic goals and outlines strategic
achievements in alignment with NCIRD priorities; (4) monitors and
evaluates progress of division- and branch-led programs, promotes
program improvements, and facilitates strategic decision-making; (5)
provides analysis and facilitates strategic use of public health
policies and operational procedures for continuous risk management and
operational efficiencies; (6) identifies needs and allocates resources
for ongoing and new initiatives and assigns responsibilities for their
development; (7) communicates division public health messages to
internal and external audiences via conventional media, web, social
media, professional organizations, and other venues, to maximize impact
of division programs; (8) provides leadership and guidance in policy
formulation, partnerships, program planning and development, program
management, and operations of the division; (9) provides division
leadership, expertise, and technical collaboration for the application
of statistics, economics, operations research, geospatial analysis,
other quantitative sciences, informatics, and data management to
prevent disease, disability and death through immunization and control
of enteric, and other viral diseases; (10) provides next-generation
sequencing laboratory support for method development and bioinformatics
infrastructure across division and with external partners; (11)
provides leadership for division informatics, data, and surveillance
modernization initiatives; (12) prepares, reviews, and coordinates
informational, scientific, and programmatic documents; (13) assures the
overall quality of the science conducted by the division and provides
guidance and new initiatives to support the enhancement of laboratory
quality and bio-safety; (14) oversees and facilitates the division's
scientific support to other groups within CDC and national and
international public health and healthcare partners; (15) guides and
facilitates efficient coordination and cooperation for administrative,
programmatic, and scientific activities within the division and with
other groups inside and outside of CDC; (16) coordinates program and
Division-level pandemic preparedness activities related to current and
known threats such as COVID-19 and preparedness for future or emerging
threats; (17) advises NCIRD and CDC leadership in the areas of pandemic
preparedness and response and global health related to respiratory and
vaccine preventable diseases including establishing CRVD priorities,
promoting science, policies, and new programs; (18) coordinates across
NCIRD, CDC, and with partners to plan for and exercise responses to
pandemic and other threats; and (19) supports the division and all
branches through a management and operations hub, providing functional
support such as budget, program resource management, extramural
administration, and human resource management.
Coronavirus and Other Respiratory Viruses Laboratory Branch (CVGHB)
(1) Designs and conducts studies of the biological, genetic, and
antigenic characteristics of non-influenza respiratory viruses
including SARS-CoV-2, the virus the causes COVID-19, and the immunology
and pathogenesis of associated diseases; (2) designs and conducts
laboratory-related activities to support surveillance and epidemiologic
studies, and to monitor impact of vaccination and other respiratory
virus prevention measures; (3) provides laboratory support and
technical expertise for studies to define patterns and risk factors for
respiratory virus infections, diseases, and disease burden; (4)
develops, evaluates, and improves diagnostic methods and reagents,
conducts strain characterization for molecular epidemiology, and
provides technology transfer support to public health laboratories for
known and unknown viral etiologic agents for respiratory diseases of
human and animal origin; (5) characterizes immune correlates of
protection to advise partners on vaccine program policies; (6)
determines virus and host factors that impact virulence and
transmission of SARS-CoV-2 and other respiratory viruses; (7)
facilitates and participates in the evaluation of respiratory virus
countermeasures including prophylactics, therapeutics, and vaccines;
(8) provides laboratory consultation and support for investigation of
domestic and international respiratory viral disease outbreaks; (9)
serves as CDC technical lead for providing guidance to WHO and key
partners on classification of viral variants, performing variant risk
assessments to inform COVID-19 vaccination policies, as well as in
supporting platforms for genomic monitoring of coronaviruses and other
respiratory viruses; (10) provides laboratory leadership and technical
expertise to develop science-based statements to ACIP and other
domestic and international collaborators to support the development and
evaluation of practices, policies, and vaccine considerations for SARS-
CoV-2 and other respiratory viruses; and (11) provides technical
assistance to international partners to conduct comprehensive
antigenic, phenotypic, genotypic, structural, and evolutionary
characterization of SARS-CoV2 and other respiratory viruses.
[[Page 9288]]
Coronavirus and Other Respiratory Viruses Surveillance and Prevention
Branch (CVGHC)
(1) Conducts surveillance and related activities to monitor
patterns of respiratory virus infection and disease incidence and
assess impact of interventions; (2) provides technical expertise and
support to state and local health departments for surveillance and
related activities; (3) provides expertise and support on data analysis
and visualization of respiratory virus surveillance data for internal
and external use; (4) performs applied modeling analyses to
characterize disease burden and impact of interventions; (5) conducts
vaccine effectiveness evaluations for coronaviruses and other
respiratory viruses to support the development and evaluation of
immunization practices and policies; (6) analyzes and synthesizes
available data and develops science-based statements for potential
respiratory viral vaccines to support the development and evaluation of
immunization practices and policies related to coronaviruses and other
respiratory virus vaccines by ACIP and other groups; (7) Coordinates
quantitative science and data management planning, policy development,
and project monitoring and evaluation; (8) designs, develops and
conducts statistical, economic, cost, resource allocation, geospatial
and other analyses and models; (9) develops data management
methodologies and strategies for division activities and programs; and
(10) collaborates with scientists, program experts, and senior public
health officials throughout the division to implement strategies,
models, and methodologies in support of enteric, and related viral
disease research, surveillance, and prevention programs.
Coronavirus and Other Respiratory Viruses Epidemiology Branch (CVGHD)
(1) Characterizes the spectrum of disease and sequelae from
respiratory virus infections, including, but not limited to multisystem
inflammatory syndrome and post-COVID conditions, the burden and
incidence of sequelae, and risk factors for sequelae; (2) characterizes
transmission dynamics and risk factors for coronavirus and other
respiratory virus infections; (3) characterizes acute and long-term
immunity to understand correlates of protection; (4) conducts and
supports field epidemiologic studies to characterize unusual disease
clusters and unexpected disease manifestations or trends of viral
respiratory diseases; (5) provides consultation and technical
assistance to state and local health departments and others in the
investigation, management, mitigation and control of viral respiratory
disease clusters and outbreaks; (6) evaluates the implementation,
effectiveness and impact of community-level mitigation measures; (7)
develops and updates public health guidance on community-based non-
pharmaceutical interventions for the prevention and control of
respiratory viruses, such as masking, screening, quarantine, and
isolation; and (8) provides consultation and technical support on
clinical management and secondary prevention for respiratory viral
diseases.
Global Coronavirus and Other Respiratory Viruses Branch (CVGHE)
(1) Implements global respiratory virus surveillance including
supporting enhanced epidemiologic and laboratory capacity and data
analyses to improve understanding of the epidemiological
characteristics, trends, and emergence of respiratory pathogens; (2)
builds capacity for global surveillance and epidemic intelligence to
detect and respond to respiratory events including those of pandemic
potential; (3) assists global partners in pandemic preparedness
activities; (4) provides support and/or participates in investigations
of international respiratory outbreaks including implementing
appropriate control measures; (5) conducts research studies with global
partners, division, and agency stakeholders to better understand burden
of disease, impact of prevention programs, and molecular epidemiology
of respiratory viruses; (6) provides technical assistance to global
partners to conduct or support comprehensive antigenic, phenotypic,
genotypic, structural, and evolutionary characterization of SARS-CoV-2
and respiratory viruses; and (7) provides expertise to global partners
in the development of evidence-based surveillance standards and
methods.
Delegations of Authority
All delegations and redelegations of authority made to officials
and employees of affected organizational components will continue in
them or their successors pending further redelegation, provided they
are consistent with this reorganization.
(Authority: 44 U.S.C. 3101)
Xavier Becerra,
Secretary, Department of Health and Human Services.
[FR Doc. 2023-02930 Filed 2-10-23; 8:45 am]
BILLING CODE 4160-18-P